TABLE 5.
The class and list of fixed-combination medications.
| Classes | Medications | IOP reduction | Current market status | Usage, dosage | Mechanism |
|---|---|---|---|---|---|
| Prostaglandin analogs and β-blockers | Latanoprost/Timolol | 32–38% | On the market | Once daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| Bimatoprost/Timolol | |||||
| Travoprost/Timolol | |||||
| Tafluprost/Timolol | |||||
| Latanoprost/carteolol | |||||
| Prostaglandin analogs and Rho-kinase inhibitors | Latanoprost/Netarsudil | 31–37% | On the market | Once daily | Increasing uveoscleral outflow; Reducing aqueous humour formation; Increasing trabecular outflow; Reducing episcleral venous pressure |
| Prostaglandin analogs and α-2 adrenergic agonists | Bimatoprost/Brimonidine | 25–33% | Phase II | Once daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| Prostaglandin analogs and Carbonic anhydrase inhibitor | Travoprost/Brinzolamide | 25–33% | Phase III | Twice daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| Latanoprost/Dorzolamide | — | Phase II | |||
| β-blockers and α-2 adrenergic agonists | Timolol/Brimonidine | 28–34% | On the market | Twice daily | Increasing uveoscleral and trabecular outflow; Reducing aqueous humour formation |
| β-blockers and Carbonic anhydrase inhibitors | Timolol/Brinzolamide | 28–35% | On the market | Twice daily | Reducing aqueous humour formation |
| Timolol/Dorzolamide | 29–34% | ||||
| α-2 adrenergic agonists and Carbonic anhydrase inhibitors | Brinzolamide/Brimonidine | 21–35% | On the market | Three times daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| α-2 adrenergic agonists and Rho-kinase inhibitors | Ripasudil/Brimonidine | — | Phase III | — | Increasing uveoscleral outflow; Reducing aqueous humour formation; Increasing trabecular outflow; Reducing episcleral venous pressure |
| Prostaglandin analogs and β-blockers and α-2 agonists | Bimatoprost/Timolol/Brimonidine | — | Phase III | Twice daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| β-blockers and α-2 agonists and Carbonic anhydrase inhibitors | Dorzolamide/Timolol/Brimonidine | — | On the market | Twice daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |